Chinese ADC Developers Unveil More Target Combos In Bispecific Drive

Chinese developers are racing to roll out bispecific ADCs with different target combinations, while a Biokin/SysImmune executive estimates more than $20bn in annual sales for the company's BMS-partnered EGFR x HER3 candidate, as R&D in the field continues to surge ahead in China.

bispecific approach
bispecific approach to ADC development gains steam in China • Source: Shutterstock

Multiple Chinese developers of antibody-drug conjugates (ADCs) are now turning their focus to bispecific candidates based on different target combinations as they look to diversify their expertise in the fast-growing field.

The fresh drive for bispecifics has quickened pace over the past few months on the back of a huge licensing deal worth up to $8.4bn for the EGFR x HER3-targeting...

Key Takeaways
  • Chinese biotechs' fresh drive to develop bispecific ADCs has quickened on the back of an up to $8.4bn licensing deal with BMS for...

More from China

More from Focus On Asia